Intravenous immunoglobulin treatment of immunodeficiency:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Philadelphia [u.a.]
Saunders
2008
|
| Series: | Immunology and allergy clinics of North America
28,4 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XVI S., S. 691 - 885 |
| ISBN: | 9781416063100 1416063102 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035223920 | ||
| 003 | DE-604 | ||
| 005 | 20081222 | ||
| 007 | t | ||
| 008 | 081219s2008 |||| 00||| eng d | ||
| 020 | |a 9781416063100 |9 978-1-4160-6310-0 | ||
| 020 | |a 1416063102 |9 1-4160-6310-2 | ||
| 035 | |a (OCoLC)268958178 | ||
| 035 | |a (DE-599)BVBBV035223920 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 |a DE-355 | ||
| 050 | 0 | |a QR180 | |
| 082 | 0 | |a 616.97906 |2 22 | |
| 245 | 1 | 0 | |a Intravenous immunoglobulin treatment of immunodeficiency |c guest ed. Chaim M. Roifman |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2008 | |
| 300 | |a XVI S., S. 691 - 885 | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Immunology and allergy clinics of North America |v 28,4 | |
| 650 | 4 | |a Immunodeficiency |x Treatment | |
| 650 | 4 | |a Immunoglobulins |x Therapeutic use | |
| 650 | 4 | |a Immunoglobulins |x therapeutic use | |
| 650 | 4 | |a Immunologic Deficiency Syndromes | |
| 700 | 1 | |a Roifman, Chaim M. |e Sonstige |0 (DE-588)136906540 |4 oth | |
| 830 | 0 | |a Immunology and allergy clinics of North America |v 28,4 |w (DE-604)BV000645505 |9 28,4 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017029966&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-017029966 | ||
Record in the Search Index
| _version_ | 1804138488824594435 |
|---|---|
| adam_text | Contents
Foreword:The Question of When and How xiii
Rafeul Alam
Preface xv
Chaim M. Roifman
Hypogammaglobulinaemia 691
Patrick F.K. Yong, Ronnie Chee, and Bodo Grimbacher
This article reviews the primary immunodeficiencies that result in hypo-
gammaglobulinemia or predominantly antibody deficiency disorders.
This group makes up the largest proportion of patients with primary immu-
nodeficiency. Significant advances have been made in understanding the
molecular basis and clinical characteristics of patients with the more se-
vere forms of antibody deficiency in the last 6 years. Recognition of these
disorders remains poor with significant diagnostic delay. The milder forms
of antibody deficiency disorders, especially those with normal total serum
immunoglobulin G levels, remain poorly characterized and understood.
Further work remains to be done in understanding and recognizing these
syndromes to benefit patient care and fester further knowledge of the im¬
mune System.
Genetic Syndromic Immunodeficiencies with Antibody Defects 715
Jeffrey E. Ming and E. Richard Stiehm
This article reviews the major syndromic immunodeficiencies with
significant antibody defects, many of which may require intravenous im-
munogammaglobulin therapy. The authors define syndromic immunodefi-
ciency as an illness associated with a characteristic group of phenotypic
abnormalities or laboratory features that comprise a recognizable syn-
drome. Many are familial with a defined inheritance pattern. Immunodefi-
ciency may not be a major part of the illness and may not be present in
all patients; thus, these conditions differ from primary immunodeficiency
syndromes, in which immune abnormalities are a consistent and promi¬
nent feature of their disease.
History of Immunoglobulin Replacement 737
Martha M. Eibl
The Provision of antibodies to prevent and treat infection began with the
application of curative serum in the first years of the last Century. After
the process of large-scale plasma fractionation was developed in the
1940s, the general use of immunoglobulin expanded. Intravenous immu¬
noglobulin products became available in the 1970s, and their only use
for the Provision of antibodies governed the opinion of experts over the
next decade. Modulation of inflammation and immunosuppression were
introduced in treatment of inflammatory and autoimmune diseases and
became accepted indications. The history of adverse events of treatment
and their management are outlined in this article. Consensus indications
and evidence-based off-label uses are discussed.
Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations 765
John A. Hooper
Since its first use in 1952, human immunoglobulin has been used to treat
people who have inherited antibody deficiencies. This article summarizes
IVIG clinical development in primary immunodeficient patients and
manufacturing improvements introduced over time. Manufacturing im-
provements include purification procedures that have reduced the inci-
dence of adverse events and improved clinical efficacy, as well as virus
inactivation and removal Steps that have increased safety from blood-
borne infections. Current manufacturing procedures, IVIG production
trends, and recent clinical trial results are also reviewed.
Subcutaneous Administration of IgG 779
Melvin Berger
The availability of IgG preparations that could be administered safely by
the intravenous route was finally achieved in the early to mid-1980s. Intra¬
venous immunoglobulin (IVIG) revolutionized the treatment of primary
immune deficiency diseases (PIDD) and led to the discovery of the thera-
peutic value of high-dose IgG in autoimmune and inflammatory diseases
not associated with PIDD. Improved therapy has improved outcomes
and expectations, and most PIDD patients can lead fully active and pro-
ductive lives. Administration of IgG by the subcutaneous route is effective
and safe and overcomes obstacles to the use of IVIG in some patients.
Many patients find administration of subcutaneous IgG at home more con-
venient than receiving IVIG at the Doctor s Office or hospital. The Coming
years will see increased use of subcutaneous immunoglobulin in PIDD,
which will be facilitated by advances leading to higher-concentration IgG
products and easier delivery.
Pharmacokinetics of Immunoglobulin Administered via Intravenous
or Subcutaneous Routes 803
Francisco A. Bonilla
This artlcle reviews pharmacokinetic studies of IgG administration by intra¬
venous and subcutaneous routes. Intravenous immunoglobulin pharma¬
cokinetics have been studied during replacement therapy for primary
and secondary immunodeficiencies and other Special circumstances
(eg, infection prophylaxis in neonates). Subcutaneous immunoglobulin
pharmacokinetics have been studied only during replacement therapy
for primary immunodeficiency. Published studies vary greatly with respect
to the nature of the patients studied, dose regimens, sampling schedules,
and pharmacokinetic modeis, making comparisons difficult. With either
route of administration, there is large Variation in individual IgG elimination
rates. Periodic measurement of serum IgG concentration is critical to mon-
itor the adequacy of replacement during therapy.
Self-infusion Programmes for Immunoglobulin Replacement at Home:
Feasibility, Safety and Efficacy 821
Malini V. Bhole, Janet Burton, and Helen M. Chapel
This review of the currently available literature from more than two de-
cades of clinical experience with self-infusions of immunoglobulin at
home provides evidence to support the feasibility, safety, and efficacy in
all age groups. Self-infusions at home not only increase patient confidence
and their understanding of the immune deficiency but also contribute to
the improvement of health-related quality of life. Such home therapy pro-
grams should be encouraged, and wherever possible, experienced
centers should extend their Services to include patients who require immu¬
noglobulin therapy for immunomodulation. Home therapy programs play
an important role in long-term health outcome.
Immunoglobulin Replacement Therapy in Children 833
Maria Garcia-Lloret, Sean McGhee, and Talal A. Chatila
The benefit of immunoglobulin (IG) replacement in primary antibody defi-
ciencies is unquestionable. Many of these congenital disorders present
early in life and this therapy is often first implemented in the young. This
article focuses on the indications of IG replacement in children, with an
emphasis on the specific diagnostic problems encountered in this popula-
tion. Also presented is an overview of the practical aspects of IG adminis¬
tration in the pediatric setting, including the recognition and management
of adverse reactions. Finally, the advent of subcutaneous IG, a therapeutic
IG modality with the potential to have a great impact on the quality of life of
children with antibody deficiencies and their families, is discussed.
Intravenous GammaglobulinTreatment in HIV-1 Infection 851
Avi Deener, Ami Mehra, Larry Bernstein, Jenny Shliozberg,
and Arye Rubinstein
The two main indications for the use of intravenous gammaglobulin—anti-
body replacement therapy and immunomodulation—are pertinent only for
a few scenarios in HIV-1 infection. The role of gammaglobulin in the treat-
ment of HIV-1 infection has changed significantly with the introduction of
highly active antiretroviral therapy. Antiretroviral drugs have not only con-
trolled the Progression of disease but also had far-reaching effects on HIV-
1-induced immunologic aberrations. Complete or partial immunologic
reconstitution and prevention of immunologic damage have been the hall-
marks of success for highly active antiretroviral therapy. This article ad-
dresses the use of gammaglobulin before and after the era of effective
antiretroviral therapies.
Economic Assessment of Different Modalities of Immunoglobulin
Replacement Therapy 861
Stephen K. Membe, Chuong Ho, Karen Cimon, Andra Morrison,
Amin Kanani, and Chaim M. Roifman
The delivery (intravenous or subcutaneous), location (home or hospital),
and other factors of immunoglobulin replacement therapy are examined
for cost effectiveness. Cost-minimization studies from several countries
are reviewed and analyzed. A Canadian cost-minimization study is per-
formed. Although common themes emerge, there are cost differences be-
tween the various countries.
Management of PrimaryAntibody Deficiency with Replacement Therapy:
Summary of Guidelines 875
Chaim M. Roifman, Melvin Berger, and Luigi D. Notarangelo
This article summarizes the guidelines for using replacement therapy in the
management of patients who have primary antibody deficiency.
Index 877
|
| any_adam_object | 1 |
| author_GND | (DE-588)136906540 |
| building | Verbundindex |
| bvnumber | BV035223920 |
| callnumber-first | Q - Science |
| callnumber-label | QR180 |
| callnumber-raw | QR180 |
| callnumber-search | QR180 |
| callnumber-sort | QR 3180 |
| callnumber-subject | QR - Microbiology |
| ctrlnum | (OCoLC)268958178 (DE-599)BVBBV035223920 |
| dewey-full | 616.97906 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.97906 |
| dewey-search | 616.97906 |
| dewey-sort | 3616.97906 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01470nam a2200373 cb4500</leader><controlfield tag="001">BV035223920</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20081222 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">081219s2008 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416063100</subfield><subfield code="9">978-1-4160-6310-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416063102</subfield><subfield code="9">1-4160-6310-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)268958178</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035223920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR180</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.97906</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous immunoglobulin treatment of immunodeficiency</subfield><subfield code="c">guest ed. Chaim M. Roifman</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI S., S. 691 - 885</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">28,4</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunodeficiency</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunoglobulins</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunoglobulins</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunologic Deficiency Syndromes</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roifman, Chaim M.</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)136906540</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">28,4</subfield><subfield code="w">(DE-604)BV000645505</subfield><subfield code="9">28,4</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017029966&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017029966</subfield></datafield></record></collection> |
| id | DE-604.BV035223920 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T21:28:59Z |
| institution | BVB |
| isbn | 9781416063100 1416063102 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-017029966 |
| oclc_num | 268958178 |
| open_access_boolean | |
| owner | DE-29 DE-355 DE-BY-UBR |
| owner_facet | DE-29 DE-355 DE-BY-UBR |
| physical | XVI S., S. 691 - 885 |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Saunders |
| record_format | marc |
| series | Immunology and allergy clinics of North America |
| series2 | Immunology and allergy clinics of North America |
| spelling | Intravenous immunoglobulin treatment of immunodeficiency guest ed. Chaim M. Roifman Philadelphia [u.a.] Saunders 2008 XVI S., S. 691 - 885 txt rdacontent n rdamedia nc rdacarrier Immunology and allergy clinics of North America 28,4 Immunodeficiency Treatment Immunoglobulins Therapeutic use Immunoglobulins therapeutic use Immunologic Deficiency Syndromes Roifman, Chaim M. Sonstige (DE-588)136906540 oth Immunology and allergy clinics of North America 28,4 (DE-604)BV000645505 28,4 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017029966&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Intravenous immunoglobulin treatment of immunodeficiency Immunology and allergy clinics of North America Immunodeficiency Treatment Immunoglobulins Therapeutic use Immunoglobulins therapeutic use Immunologic Deficiency Syndromes |
| title | Intravenous immunoglobulin treatment of immunodeficiency |
| title_auth | Intravenous immunoglobulin treatment of immunodeficiency |
| title_exact_search | Intravenous immunoglobulin treatment of immunodeficiency |
| title_full | Intravenous immunoglobulin treatment of immunodeficiency guest ed. Chaim M. Roifman |
| title_fullStr | Intravenous immunoglobulin treatment of immunodeficiency guest ed. Chaim M. Roifman |
| title_full_unstemmed | Intravenous immunoglobulin treatment of immunodeficiency guest ed. Chaim M. Roifman |
| title_short | Intravenous immunoglobulin treatment of immunodeficiency |
| title_sort | intravenous immunoglobulin treatment of immunodeficiency |
| topic | Immunodeficiency Treatment Immunoglobulins Therapeutic use Immunoglobulins therapeutic use Immunologic Deficiency Syndromes |
| topic_facet | Immunodeficiency Treatment Immunoglobulins Therapeutic use Immunoglobulins therapeutic use Immunologic Deficiency Syndromes |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017029966&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000645505 |
| work_keys_str_mv | AT roifmanchaimm intravenousimmunoglobulintreatmentofimmunodeficiency |